Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov;94(5):570-3.
doi: 10.1038/clpt.2013.153. Epub 2013 Jul 26.

Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy

J P Lewis  1 , L M Yerges-Armstrong, S Ellero-Simatos, A Georgiades, R Kaddurah-Daouk, T Hankemeier
Affiliations
Review

Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy

J P Lewis et al. Clin Pharmacol Ther. 2013 Nov.

Abstract

Interindividual variability in response to antiplatelet therapy results in higher platelet reactivity as well as higher rates of cardiovascular events. Despite substantial effort, the genetic and nongenetic determinants of antiplatelet variability remain poorly understood. Emerging pharmacometabolomic paradigms that integrate systems approaches such as pharmacogenomics have the potential to unveil novel biology regarding disease pathogenesis, reveal the effect of drugs on pathways, and allow better understanding of response variability. Such approaches offer great potential for personalized antiplatelet treatment.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

R.K.-D. has patents in the field of metabolomics. The other authors declared no conflict of interest.

Figures

Figure 1
Figure 1
Example paradigm for pharmacometabolomic investigation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abo R, et al. Merging pharmacometabolomics with pharmacogenomics using ‘1000 Genomes’ single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics. 2012;22:247–253. - PMC - PubMed
    1. Ji Y, et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther. 2011;89:97–104. - PMC - PubMed
    1. Mitchell BD, et al. The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. Am Heart J. 2008;155:823–828. - PMC - PubMed
    1. Yerges-Armstrong LM, et al. Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther. 2013;94:525–532. - PMC - PubMed
    1. Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci USA. 1999;96:5292–5297. - PMC - PubMed

Publication types

MeSH terms